| Description |
Propantheline is an orally active mAChR antagonist. Propantheline can be used in the research of smooth muscle dysfunction, excessive sweating, cramps or spasms of the stomach, intestines or bladder, and involuntary urination[1][2][3].
|
| Related Catalog |
|
| Target |
mAChR[1]
|
| In Vitro |
Propantheline (10 μM-1 mM) decreases urinary bladder smooth muscle reactivity to Acetylcholine[1].
|
| In Vivo |
Propantheline (oral administration, 10-300 mg/kg) decreased the fecal pellet count and the incidences diarrhea in restraint stress-induced bowel dysfunction rats[3]. Animal Model: Restraint stress-induced bowel dysfunction models in rats[3] Dosage: 10-300 mg/kg Administration: Oral administration Result: Decreased the fecal pellet count with ED50 values of 41 mg/kg. Dose-dependently decreased the incidences of diarrhea with ED50 values of 64 mg/kg.
|
| References |
[1]. J Mokry, et al. Propantheline and in vitro reactivity of urinary bladder smooth muscle in guinea pigs. Bratisl Lek Listy. 2005;106(4-5):151-4. [2]. Richard Jewell, et al. Propantheline. xPharm: The Comprehensive Pharmacology Reference. 2007, Pages 1-5. [3]. S Kobayashi, et al. Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. Jpn J Pharmacol. 2001 Jul;86(3):281-8.
|
